NIH Campaign Materials

Agenda and Fact Sheet

Meeting Agenda

Humanitarian Licensing Fact Sheet

Background Information

U.S. Federal Rights in Patents, presentation by James Love of Knowledge Ecology International, September 14, 2011

Statutory Basis for Making Licenses to Federally-Funded Patented Inventions Available to International Organizations and Developing Countries

dicins Sans Frontières: "Untangling the Web of ARV Price Reductions: Background" (see pages 6-10)

Universities Allied for Essential Medicines report, "The Global Health Impact of University Research and Intellectual Property"

"Patents vs. Patients: Five Years After the Doha Declaration" (links to

Ritonavir Fact Sheet

Medicines Patent Pool, "Mission," (links to

Medicines Patent Pool, "Background," (links to

KEI: Federal Rights in Patents in FDA Orange Book July 28, 2011

KEI: Drugs with Some US Government Rights in the Patents in FDA Orange Book, August 2011

KEI: Patents for Drugs for AIDS in FDA Orange Book, August 1, 2011

KEI: "Alpha" Cancer Product patents in FDA Orange Book

KEI: Bayh-Dole Timeline (links to

Previous Requests

Excerpts from: Testimony of Robert Weissman, "The Role of Federally-Funded University Research in the Patent System" Before the Committee of Judiciary, U.S. Senate, October 24, 2007

Essential Inventions Letter to Robert Portman, January 5, 2007

Response letter from US Secretary of Health and Human Services Tommy Thompson to Ralph Nader (links to July 6, 2001

Letter from Ralph Nader, James Love, and Robert Weissman to US Secretary of Health and Human Services Tommy Thompson (links to March 28, 2001

Response letter from NIH Director Dr. Harold Varmus to Ralph Nader, James Love, Robert Weissman (links to October 19th, 1999

Letter from Ralph Nader, James Love, Robert Weissman to Dr Harold Varmus, Director of the NIH (links to September 3, 1999

Back to NIH Campaign Page

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.